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Abstract
Background: Many members of the ETS-domain transcription factor family are important drivers of
tumourigenesis. In this context, their activation by Ras-ERK pathway signaling is particularly relevant to the
tumourigenic properties of many ETS-domain transcription factors. The PEA3 subfamily of ETS-domain transcription
factors have been implicated in tumour metastasis in several different cancers.
Results: Here, we have studied the expression of the PEA3 subfamily members PEA3/ETV4 and ER81/ETV1 in
oesophageal adenocarcinomas and determined their role in oesophageal adenocarcinoma cell function. PEA3 plays
an important role in controlling both the proliferation and invasive properties of OE33 oesophageal
adenocarcinoma cells. A key target gene is MMP-1. The ERK MAP kinase pathway activates PEA3 subfamily
members and also plays a role in these PEA3 controlled events, establishing the ERK-PEA3-MMP-1 axis as important
in OE33 cells. PEA3 subfamily members are upregulated in human adenocarcinomas and expression correlates with
MMP-1 expression and late stage metastatic disease. Enhanced ERK signaling is also more prevalent in late stage
oesophageal adenocarcinomas.
Conclusions: This study shows that the ERK-PEA3-MMP-1 axis is upregulated in oesophageal adenocarcinoma cells
and is a potentially important driver of the metastatic progression of oesophageal adenocarcinomas.
Introduction
Oesophageal adenocarcinoma is a devastating disease
that has been rising year on year over the past three dec-
ades and is the 6
th highest cause of cancer mortality in
the UK, accounting for around 5% of all cancers [1,2].
The escalating incidence is thought to be a result of the
combination of an obesity epidemic, an aging population,
and H. pylori eradication [3-5]. The disease is curable by
surgery or endoscopic therapy if diagnosed at a very early
stage [6] but usually, diagnosis is made at an advanced
stage with the presence of lymph node and distant metas-
tases [5]. There are few clear prognostic indicators of sus-
ceptibility to developing oesophageal adenocarcinoma
although patients with Barrett’so e s o p h a g u sa r et h o u g h t
to be more at risk to developing oesophageal adenocarci-
noma. However, the progression from Barrett’s oesopha-
gus to dysplasia and subsequent adenocarcinoma
is unpredictable and poorly understood [7]. The lack of
prognostic indicators results in presentation of patents at
late disease stages, resulting in poor five year survival
rates and patients usually succumb to disease re-occur-
rence [5,8]. For a significant majority, surgery is not
beneficial and in such patients with distant metastases,
survival is limited to 9 months [9-11]. If the situation is
to change then a deeper understanding of tumour growth
and metastases is needed to identify new treatment
targets.
The ETS domain transcription factor family consists
of a group of 27 proteins in humans that all contain the
conserved ETS DNA-binding domain and share a core
DNA binding specificity centred around the sequence
GGA
A/T [12,13]. The PEA3 subfamily includes three
transcription factors, PEA3 (also known as ETV4 and
E1AF), ER81 (also known as ETV1) and ERM (also
known as ETV5). These proteins all contain three con-
served domains with sequence identity of 95%, 85% and
50% in the ETS, acidic and Ct domains respectively [14].
This similarity potentially allows for an overlap in PEA3
subfamily function through acting on a common set of
target gene promoters. Indeed due to their conserved
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binding has been observed more generally amongst ETS
domain transcription factors [15,16]. The PEA3 subfam-
ily plays an important role in embryogenesis, especially
in neurogenesis [17] and also in mammary gland devel-
opment [14,18,19]. In the adult, PEA3 subfamily mem-
bers are generally expressed at lower levels and in a
more restrictive manner [14] but ETS domain proteins,
and especially the PEA3 subfamily are associated with
carcinogenesis, especially tumour metastases and their
overexpression often indicates adverse prognosis [14,20].
This has been shown to be the case in breast cancer,
colon cancer, ovarian cancer and gastric cancer [14].
More recently, high expression levels of ER81 have been
shown to occur in prostate cancer as a result of chro-
mosomal translocations of the ER81 gene into loci with
high promoter activity in prostate cells [21,22]. PEA3
expression often correlates with enhanced invasive prop-
erties and hence is associated with metastasis. For exam-
ple, in gastric cancer and colon cancer cells, PEA3
inhibition reduces cell invasion in vitro [23,24]. Conver-
sely, PEA3 over-expression induces an invasive pheno-
type in breast and ovarian cancer cells [25,26]. Similarly
ER81 over-expression enhances the invasive capabilities
of prostate cancer cells [22]. The invasive phenotypes of
cells with high PEA3 subfamily expression are thought
to be due in part to their ability to regulate the expres-
sion of matrix metalloproteases (MMPs) [20]. MMP1
has been shown to be an adverse marker in oesophageal
adeoncarcinoma [27,28]. In colon and gastric cancer cell
lines, PEA3 has been shown to regulate MMP-1 and
MMP-7 expression [23,24]. A potential link between
PEA3 and MMP7 expression was also suggested in stu-
dies on oesophageal squamous carcinoma cells [29].
MAP kinase signalling is also important in PEA3 activa-
tion [30,31] in part through driving its dynamic sumoy-
lation [32]. Importantly MAP kinase signaling synergises
with PEA3 in MMP activation as demonstrated by
enhanced MMP-9 and MMP-14 production in response
to EGFR signaling in ovarian cancer [25]. These obser-
vations indicate that PEA3 subfamily members are likely
central regulators in carcinogenesis and are potential
therapeutic targets.
A unifying view of PEA3 function in cancer is there-
fore that it is a regulator of MMP expression in
response to ERK MAP kinase pathway signaling. How-
ever, to date few studies have connected these molecular
events together in a single system and the potential role
of PEA3 subfamily members in oesophageal adenocarci-
noma has not previously been investigated. Indeed, none
of the wider ETS domain transcription factor family has
been implicated in oesophageal adenocarcinoma,
although Ets-1, Ets-2 and Elk-1 have been shown to be
over-expressed on squamous oesophageal cancers
[33-35]. Here, we show that high PEA3 expression is a
frequent occurrence in oesophageal adenocarcinoma. In
oesophageal adenocarcinoma cell line models, PEA3
plays a role in promoting invasion and is also important
for oesophageal cell proliferation. Molecularly, the inva-
sive properties are likely due to the activation of MMP-
1 expression. Furthermore we also show an important
role of the ERK pathway in promoting PEA3 activity
and ensuing invasion. In adenocarcinoma tissue, the
co-occurrence of PEA3 family member expression corre-
lates with enhanced MMP-1 expression. Active ERK
signaling correlates with enhanced stage suggesting an
important role in promoting metastasis via PEA3 and
ER81. These results indicate that the ERK-PEA3-MMP-
1 axis identified in oesophageal cancer cells is also likely
to be operative in oesophageal adenocarcinoma tissue.
This pathway could potentially be targeted by drug inhi-
bition with a view to improve prognosis.
Results
The expression of PEA3 family members in oesophageal
tissues
To establish whether members of the PEA3 subfamily
ETS-domain transcription factors might play a role in
oesophageal adenocarcinomas, we first determined the
expression of PEA3 protein in normal oesophageal
tissue and oesophageal adenocarcinomas by construct-
ing a TMA from 27 samples from normal patients and
58 samples from oesophageal adenocarcinomas, along
with samples from adjacent normal tissue. We also
included 23 samples from patients with Barrett’so e s o -
p h a g o u sa st h i si st h o u g h tt ob eap r e c u r s o rc o n d i t i o n
to adenocarcinoma development [7]. Samples were
then scored as PEA3 positive if they had moderate-
high PEA3 protein levels (Figure 1A). Very few normal
or Barrett’s samples contained moderate-high PEA3
protein levels (4%) but in contrast, over 33% of sam-
ples from adenocarcinomas exhibited moderate-high
PEA3 protein levels (Figure 1B). Importantly, when we
split the adenocarcinomas into T and N stage tumours,
the frequency of occurrence of high PEA3 protein
levels was significantly higher in the nodal (N stage)
tumours, suggesting an association of PEA3 expression
with metastasis (Figure 1C).
In addition to analysing protein levels, we also deter-
mined the levels of PEA3 mRNA in oesophageal tissue
samples alongside the levels of the related subfamily
member ER81.T h el e v e l so fPEA3 and ER81 mRNA
were generally low in samples from normal tissue or
Barrett’s patients (Additional file 1: Figure S1; Figure 1D
and 1E; see also Figure 6 A). In contrast, samples from
oesophageal adenocarcinomas generally showed higher
levels of either PEA3, ER81 or both transcription factors
(Additional file 1: Figure S1; 1D and 1E; see also
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29 (79%) showed levels of either PEA3 or ER81, or both,
that were higher than found in samples from normal
tissue.
Together these data therefore provide strong evidence
which associates PEA3 and ER81 expression with adeno-
carcinomas, and association with patient parameters
suggests that PEA3 expression is associated with meta-
static disease.
The expression of PEA3 family members and their target
genes in oesophageal cell lines
Next we investigated whether oesophageal cell lines
showed similar characteristics to the tumour samples.
Two cell lines derived from oesophageal adenocarcino-
mas, Flo-1 and OE33 cells were tested alongside OE21
oesophageal squamous cancer cells, and Het1A, a cell
line derived from normal oesophageal epithelial tissue.
S W 4 8 0a n d2 9 3 Tc e l l sw e r eu s e da sc o n t r o l sa st h e s e
Figure 1 PEA3 and ER81 mRNA and protein expression in oesophageal adenocarcinomas. (A) Examples of TMA staining for PEA3 protein
(brown stain in right hand panels) in normal epithelium and adenocarcinoma samples at × 20 magnification. H&E staining of the same samples
is shown on the left. (B) Summary of TMA data for moderate-high PEA3 expression in patient samples from different tissue classes. (C) The
proportion of patients with T stage or N stage disease, with high PEA3 protein expression. (D and E) Box plots of PEA3 (D) and ER81 (E) mRNA
expression in oesophageal tissue taken from healthy controls, Barrett’s oesophagus and oesophageal adenocarcinoma patients. Median relative
expression levels of PEA3 and ER81 are indicated for each tissue type. mRNA expression is calculated relative to 18S ribosomal RNA. The box plot
represents the inter-quartile range and the median value is indicate by the horizontal line. The y axes are split (indicated by dashed lines) and
the high outliers are labelled by case number.
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respectively for PEA3 expression [23,36]. Both of the
adenocarcinoma cell lines showed detectable PEA3
mRNA expression whereas normal Het1A cells showed
little expression (Figure 2A, panel 1, lanes 3-5). Low
levels of ER81 mRNA were seen in all cell lines, except
OE21 where it was barely detectable and Flo1 cells
where high level expression was observed (Figure 2A,
panel 2). These results were confirmed in OE33 and
Het1A cells by real-time PCR, where PEA3 levels are
clearly greatly elevated in OE33 cells (Figure 2B). OE33
and Het1A cells therefore represent reasonable models
in which to study PEA3 function as PEA3 expression
mirrors that seen in tissue samples, being high in adeno-
carcinomas and low in normal oesophageal cells.
PEA3 has been shown to control the expression of
several matrix metalloproteases, including MMP-1
[23,36] and MMP-7 [24], and other genes such as osteo-
pontin [37] and VEGF [38]. We therefore examined
whether PEA3 presence correlated with expression of
any of these potential targets in the cell line models.
MMP-1 was expressed in both OE21 and OE33 cell
lines, alongside PEA3 suggesting a causal relationship
(Figure 2A, panel 3, lanes 3 and 4). These results were
confirmed in OE33 and Het1A cells by real-time PCR,
where MMP-1 levels are clearly greatly elevated in OE33
Figure 2 PEA3 expression and MMP-1 regulation. (A) RT-PCR analysis of PEA3, ER81, MMP-1, MMP-7 and osteopontin mRNA expression in the
indicated cell lines. GAPDH was used as a loading control. (B-D) Real time RT-PCR analysis of PEA3, ER81, MMP-1 and the indicated putative
target genes in untreated Het1A and OE33 cells (B) or OE33 oesophageal adenocarcinoma cells treated with SMARTpool siRNAs directed against
PEA3 (C) or ER81 (D). Average mRNA levels (from duplicate samples in 2 experiments) were calculated relative to the respective mRNA levels of
each gene in OE33 cells (B) or to cells treated with a non targeting siRNA (C and D) (taken as 1). (E-G) Real time RT-PCR analysis of PEA3 (E), ER81
(F) and MMP-1 (G) expression in OE33 cells treated with SMARTpool (sp) siRNAs directed against PEA3 or ER81 or one of four individual de-
convoluted SMARTpool component siRNAs against PEA3, denoted A-D. Average mRNA expression levels (from duplicate samples in 2
experiments) were calculated relative to the respective mRNA levels of each gene in cells treated with a non targeting siRNA (taken as 1). (H)
Reporter gene assay of the activity of a MMP-1-luciferase reporter construct in OE33 cells in the presence of the indicated siRNA duplexes. Cells
were co-transfected with either empty vector (grey bars) or with a murine PEA3 expression vector (black bars). Data are shown relative to the
activity of the reporter in the presence of non-targeting siRNA duplexes in either the presence or absence of mPEA3 (taken as 1 in both cases)
and are the average of 2 experiments performed in duplicate (+/- sem).
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to high levels in OE33 cells and reciprocally, osteopontin
was only expressed to high levels in OE21 cells (Figure
2A, panel 4, lanes 3 and 4). Flo1 cells showed little
MMP expression despite the presence of PEA3 and
ER81, indicating that these transcription factors are not
sufficient to activate MMP expression.
To further investigate the potential links between
PEA3 and ER81 and putative target gene expression,
we performed siRNA-mediated depletion experiments
in OE33 cells using SMARTpools and measured target
gene expression. Depletion of PEA3 had little effect on
GAPDH and VEGF levels, but caused a 75% reduction
in MMP-1 mRNA expression (Figure 2C). A moderate
1.6 fold rise in MMP-7 levels was observed upon PEA3
depletion (Figure 2C). In contrast, depletion of ER81
had minimal effects on potential target gene expres-
sion, although the incomplete levels of knockdown
seen with ER81 (65% reductions; Figure 2D) might
mask potential effects which would be revealed by
complete knockdown. Interestingly, ER81 levels were
reduced upon PEA3 depletion (Figure 2C) and recipro-
cally, PEA3 levels were reduced upon ER81 depletion,
although to a lesser extent, (Figure 2D) suggesting
potential cross-regulation (see discussion). To verify
these results, we deconvoluted the PEA3 SMARTpool
siRNAs and analysed the effects on MMP-1 expression.
First we confirmed that the individual siRNAs caused
PEA3 depletion, and all showed efficient depletion of
PEA3 levels (78-99% reductions; Figure 2E) but also
impacted on ER81 levels, albeit to a lesser extent (64-
95% reductions; Figure 2F). Importantly, three of the
four individual siRNA constructs also caused reduc-
tions in MMP-1 levels (Figure 2G) with the exception
of siRNA-B which presumably triggers a compensatory
off target effect. To confirm the specificity of the
siRNA effects, we performed a rescue experiment with
murine PEA3 expression constructs. siRNA constructs
A, C and D all caused similar reductions in the activity
of a MMP-1 promoter-driven reporter construct to
those observed on the expression of the endogenous
gene (Figure 2H). Re-introduction of wild-type PEA3
protein, caused a reversal of the siRNA effects, demon-
strating that the loss of PEA3 was at least in part
responsible for the reduced MMP-1 levels observed.
However, as PEA3 depletion also results in decreased
ER81 levels, we cannot definitively conclude that PEA3
is directly responsible for all of the downstream effects
on MMP-1 expression and cell behaviour, although it
is clearly a major contributory factor.
Together these results therefore establish OE33 cells
as a useful model to study PEA3 function in adenocarci-
noma cells as they express both PEA3,a n di t st a r g e t
gene MMP-1. Furthermore PEA3 is necessary for
MMP-1 expression in these cells. Importantly PEA3
family expression is not sufficient for MMP expression
in all cell lines as MMP-1 and -7 are not highly
expressed in Flo1 cells despite the expression of these
transcription factors.
Comparative analysis of oesophageal cell phenotypes
We have demonstrated that the gene expression pro-
files of the OE33 oesophageal adenocarcinoma cells
differ from Het1A oesophageal epithelial cells and we
wanted to know if the phenotypes of these cell lines
also differed. First we used Matrigel invasion chambers
to assess the capacity of these cells to migrate and
invade in vitro. OE33 cells displayed a 3 fold increase
in invasive potential when compared to Het1A cells
(Figure 3A). This difference is consistent with the
higher MMP-1 expression seen in OE33 cells, as
MMP-1 is often associated with metastatic-like inva-
sive properties.
Next we compared the proliferation of several oeso-
phageal cell lines by counting the cells over a 7 day per-
iod. Het1A cells were compared to OE33 and Flo-1
cells. All of the cell lines proliferate exponentially. How-
ever the OE33 and Flo-1 adenocarcinoma-derived cells
proliferate quicker than the Het1A cells (Figure 3B).
Similar levels of cell death were seen in all cases, indi-
cating that increased survival was not responsible for
the higher numbers of cells observed with the adenocar-
cinoma cell lines (data not shown).
Together, these results establish that OE33 adenocar-
cinoma cells exhibit a higher invasive potential and
growth rate than the non tumourigenic Het1A cells.
PEA3 is required for the increased invasion and
proliferation in OE33 cells
PEA3 has been established as an important regulator of
cell invasion in colon cancer and gastric adenocarci-
noma cells through regulation of MMP-1 and MMP-7
respectively [23,24]. We therefore wanted to investigate
if PEA3 is also a regulator of oesophageal cancer cell
invasion. A siRNA-mediated PEA3 knockdown strategy
was employed to reduce PEA3 expression. Matrigel
invasion chambers were again utilised to assess in vitro
invasion. Het1A cells do not express PEA3 at high levels
making them a valid control for PEA3 depletion. Indeed,
depletion of PEA3 did not alter Het1A cell invasion
when compared to cells treated with control duplexes
(Figure 4A). This indicates that the PEA3 SMARTpool
is unlikely to have an ‘off target’ effect on cell invasion.
In contrast, PEA3 depletion reduced the invasive cap-
abilities of OE33 by nearly 60% (Figure 4B), indicating
that PEA3 is important for invasion by OE33 cells. To
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invasion, we asked whether MMP-1 depletion in OE33
cells would also lead to a decrease in invasion. This was
indeed the case, albeit to a lesser extent (Figure 4C),
suggesting that PEA3 likely drives invasion through
multiple targets in addition to MMP-1.
Research on PEA3 has mainly focused on its ability to
regulate MMPs and cell invasion. A previous studies in
breast and ovarian cancer cells demonstrated that PEA3
controls the expression of cell cycle regulators such as
Cyclin D3 [39] and p21 [40] respectively, and hence sug-
gested that it might be involved in controlling prolifera-
tion. We therefore investigated if PEA3 was important
for oesophageal cancer cell proliferation. First we
depleted PEA3 in Het1A cells. Over a 96 hour period,
the proliferation of Het1A cells was similar to cells trea-
ted with control duplexes (Figure 4D). In contrast,
OE33 cells treated with either SMARTpool siRNA
against PEA3 or the deconvoluted siRNA constructs A
and B, exhibited a sustained a growth arrest (Figure 4E).
In summary, PEA3 is required for the proliferation
and enhanced invasive properties of OE33 adenocarci-
noma cells.
Figure 3 Proliferative and invasive properties of oesophageal
cells. (A) Relative number of OE33 and Het1A cells invading
through a 8 μm matrigel chamber. The data are presented relative
to the number of invading OE33 cells. Data are the mean and
standard deviations of the relative number of invading cells from 3
experiments. Statistical significance was tested by the t test. (B)
Comparative analysis of the relative number of adherent Flo1, OE33
and Het1A, cells grown for 7 days. 2 × 10
4 cells were seeded at day
0 (indicated as 1). The data are representative of two independent
experiments.
Figure 4 PEA3 controls the proliferation and invasion of OE33
oesophageal adenocarcinoma cells. (A-C) Invasion assays of
Het1A (A) and OE33 (B and C) cells in the presence of siRNA
directed against PEA3, MMP-1 or a non targeting siRNA (control).
Assays were performed for 24 hours and the number of invading
cells was compared to the average number of invading cells treated
with a non targeting control (taken as 1). Data are the mean and
standard deviations of the relative number of invading cells from
duplicate samples in 2-3 independent experiments. Statistical
significance was tested by the t test. (D and E) Comparative analysis
of the relative number of adherent Het1A (D) and OE33 (E) cells
grown for 96 hours in the presence of the indicated targeting or
non-targeting (control) siRNA duplexes. SMARTpool siRNAs (D and
E) and individual siRNA contructs A and B (E) against PEA3 were
used. 2 × 10
4 cells were seeded at day 0 (indicated as 1). The data
are representative of three independent experiments, and in (D)
show the mean relative cell numbers and standard deviations from
two experiments.
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proliferation and invasion
Previous studies have demonstrated that PEA3 activity is
potentiated by ERK MAP kinase pathway signalling [14]
and that this signalling pathway plays an important role
in cancer cell properties, including invasion and prolif-
eration [41]. We therefore investigated the activation
status of this pathway in oesophageal-derived cell lines
by western analysis using an anti-phospho-ERK anti-
body. Amongst the four lines studied, phospho-ERK
levels were highest in OE33 cells, indicating that the
ERK pathway is active in these cells (Figure 5A, lane 2).
OE33 cells also contained high levels of MMP-1 and
MMP-7 protein, which is consistent with their relative
mRNA expression levels (Figure 5A, top two panels
lane 2; Figure 2A, lane 4). However, there appears to be
additional post-transcriptional events acting on MMP-1
as OE21 show more MMP-1 protein than OE33 cells
yet contain less MMP-1 mRNA (Figure 5A, top panel,
lanes 2 and 4; Figure 2A, lanes 3 and 4). In contrast,
Flo1 cells contained little MMP-1 mRNA or protein and
very low levels of phospho-ERK (Figure 5A, lane 4).
Thus the lack of ERK signaling in these cells likely
e x p l a i n sw h yM M P sa r en o th i g h l ye x p r e s s e dd e s p i t e
t h ep r e s e n c eo fP E A 3f a m i l ym e m b e r s .T ot e s tt h i s
hypothesis, we treated Flo1 cells with PMA to activate
ERK pathway signalling. A substantial increase in MMP-
1 expression was observed (Figure 5C), in keeping with
t h ei d e at h a tE R Kp a t h w a ys i g n a l l i n gi sr e q u i r e df o r
MMP-1 induction in addition to PEA3 overexpression.
Figure 5 Role of ERK MAP kinase signaling in OE33 cell function. (A) Western blot of MMP-1, MMP-7 and phospho-ERK in the indicated
oesophageal cell line extracts. ERK2 is used as a loading control. The positions of molecular weight markers are indicated. (B) Invasion assays of
OE33 cells in the presence of U0126 or DMSO (-). Assays were performed for 48 hours and the number of invading cells was compared to the
average number of invading cells treated with DMSO (taken as 1). Data are the mean and standard deviations of the relative number of
invading cells from 2-3 experiments performed in duplicate. (C) Real time RT-PCR analysis of MMP-1 expression in untreated OE33 cells or Flo1
cells treated or untreated with PMA (average of duplicate samples in 2 experiments). (D) Comparative analysis of the relative number of
adherent and OE33 cells grown for 96 hours in the presence of U0126 or DMSO (control). 2 × 10
4 cells were seeded at day 0 (indicated as 1).
The data are the mean relative cell numbers and standard deviations from two independent experiments. (E) Western blot of OE33 cell extracts
for phospho-ERK. The cells were treated with U0126 at time 0 and allowed to grow for 12 hours. ERK2 was used as a loading control. (F) Real
time RT-PCR analysis of PEA3, ER81, MMP1 and VEGF expression in OE33 cells treated with U0126 for the indicated time periods (0-12 hr).
Average mRNA levels (from duplicate samples) were calculated relative to the respective mRNA levels of each gene in cells at time zero (taken
as 1).
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in OE33 cells we used the MEK inhibitor U0126 to block
ERK signalling and investigated its effect on OE33 cell
invasion and proliferation. Both invasion (Figure 5B) and
proliferation (Figure 5D) of OE33 cells were severely
impaired upon inhibition of the ERK pathway. Finally, we
investigated whether ERK signalling impacted on the
activity of the PEA3 target gene MMP-1.T r e a t m e n to f
OE33 cells with U0126 effectively reduced ERK activation
over a sustained period (Figure 5E). Importantly, MMP-1
expression levels were also reduced (Figure 5F), consis-
tent with the known connections between ERK pathway
signalling and PEA3-mediated gene expression. We also
observed a decrease in the expression of both PEA3 and
ER81 levels upon U0126 treatment, indicating a role for
ERK pathway signalling in maintaining their expression
(Figure 5F). However, generic effects on gene expression
were not observed as VEGF was only transiently inhib-
ited, and then superinduced, suggesting regulation by
alternative mechanisms (Figure 5F).
Together, these results reveal that ERK pathway activ-
ity is elevated in OE33 adenocarcinoma cells, and plays
an important role in invasion, proliferation and the reg-
ulation of PEA3-associated gene expression.
MMP-1/-7 expression and ERK pathway signalling status
in oesophageal tissue specimens
We have demonstrated that PEA3 family members control
MMP-1 expression in oesophageal cancer cells. To estab-
lish whether PEA3 subfamily members might also play a
role in controlling MMP expression in human cancers, we
determined the levels of MMP-1 and MMP-7 mRNA
expression in tissue samples from patients with oesopha-
geal adenocarcinomas (Additional file 1: Figure S2). The
majority of adenocarcinomas showed enhanced levels of
MMP-1 (Additional file 1: Figure S2A) and/or MMP-7
(Additional file 1: Figure S2B) whereas only a few samples
from normal oesophageal epithelium or from patients
with Barrett’s metaplasia showed enhanced levels of
expression of either MMP. The data were then compared
to the expression of PEA3 and ER81 in the same samples
(Figure 6A). There is a clear clustering of samples which
express enhanced levels of either PEA3, ER81 or both and
the expression of MMP-1. In many cases, MMP-7 is also
overexpressed at the same time as PEA3 and/or ER81,
although the correlation is not as tight. This is consistent
with our findings in oesophageal cell lines where links
between PEA3 subfamily members and MMP-7 expression
were not readily apparent. Importantly, the majority of
samples that showed increased levels of both a PEA3
family member and MMP-1 were derived from
adenocarcinomas.
ERK MAP kinase signaling is an important driver of
PEA3-mediated transactivation and downstream MMP-1
expression in oesophageal adenocarcinoma-derived cell
lines. We therefore also investigated the status of ERK
pathway activation by monitoring the levels of the active
phosphorylated form of ERK (P-ERK) using the TMAs
containing samples from patients with adenocarcinomas.
Samples were then scored as P-ERK positive if more
than 5% tumour cells stained positive for P-ERK at
intensity 3-4. Samples were then grouped according to
whether they were derived from patients with AJCC
stage 1, 2, 3 and 4 disease and the P-ERK status
recorded (Figure 6B). Whereas early stage tumours
show little preference for P-ERK positivity, stage 4 sam-
ples are predominantly positive for P-ERK, suggesting a
correlation with more advanced disease. We also investi-
gated whether the presence of both high PEA3 protein
and P-ERK levels would correlate with disease severity
(Figure 6C). While high levels of either PEA3 or P-ERK
alone show only moderate association with later stage
tumour samples, there is a clear over-representation of
high levels of both P-ERK and PEA3 with late stage
tumours. As stage 3 and 4 represent metastatic stages,
this is in keeping with a role for PEA3 in promoting
metastasis in response to ERK pathway signaling. We
therefore examined whether P-ERK levels and PEA3
subfamily expression in adenocarcinoma samples might
correlate with the expression of a key driver of metasta-
sis, MMP-1. There is a general trend indicating
enhanced expression of MMP-1 i nt h ep r e s e n c eo f
either enhanced PEA3 and/or ER81 mRNA alone and
this is further increased in samples exhibiting concomi-
tant increased P-ERK levels (Figure 6C), although due to
small sample sizes, these values did not reach statistical
significance.
Together these data therefore show a clear correlation
between PEA3 subfamily member expression and the
expression of MMPs in adenocarcinoma tissue samples.
Furthermore, enhanced levels of ERK pathway signaling
combined with PEA3 expression correlate with advanced
metastatic disease. Thus, the ERK-PEA3-MMP-1 axis
which functions in oesophageal adenocarcinoma cell
lines appears to also be operative in human oesophageal
cancer.
Discussion
The PEA3 subfamily of ETS-domain transcription fac-
tors have been shown to be important drivers of cancer
cell metastasis, which is best studied in breast cancers
[14]. Here we show that PEA3 subfamily members are
overexpressed in oesophageal adenocarcinomas and pro-
mote cell proliferation and invasion in oesophageal can-
cer-derived cell lines. MMP-1 is identified as an
important target for PEA3 subfamily members in cell
line models and is co-expressed with these transcription
factors in human adenocarcinomas. Furthermore ERK
Keld et al. Molecular Cancer 2010, 9:313
http://www.molecular-cancer.com/content/9/1/313
Page 8 of 14Figure 6 Correlative expression of PEA3, ER81, MMP-1 with high levels of ERK signaling in oesophageal tissue specimens. (A) Heat map
of the relative mRNA levels of PEA3, ER81, MMP1 and MMP7 in the oesophageal tissue samples. Samples are categorized as “normal” (light grey
dots) or from patients with Barrett’s disease (dark grey dots) or oesophageal adnenocarcinomas (black dots). Expression was defined as mRNA
levels more than one standard deviation above the mean for the normal samples for each gene. Basal levels are anything below this value
(turquoise rectangles). Expression was then divided into three categories relative to the mean for the normal samples; high expression was
anything more than 100 fold (red rectangles), medium was between 25-100 fold (orange rectangles) and low was up to 25 fold (yellow
rectangles) over the mean. The primary data for individual samples is shown in additional file 1: figures S1 and S2. Groups of samples showing
increased expression of MMP-1 and either PEA3 or ER81 relative to basal levels are bracketed. (B and C) Histograms correlating the number of
patients with AJCC stage 1, 2, 3 and 4 disease and phospho-ERK (P-ERK) and PEA3 protein levels. (B) The number of patient samples showing
the presence or absence of P-ERK is correlated with each disease stage. Positive ERK MAP kinase signalling is defined as more than 5% tumour
cells staining positive for P-ERK at intensity 3-4. (C) Patients with a combination of high and low P-ERK levels and high and low PEA3 protein
expression are correlated with either early stage disease (1&2; grey bars) or late stage disease (3&4; black bars). High PEA3 protein is defined as
more than 5% tumour cells staining positive at intensity 4. Data are presented as the percentage of patients within each group representing the
indicated combinations of P-ERK and PEA3 levels. (D) Box plots of MMP1 mRNA expression in oesophageal tissue taken from oesophageal
adenocarcinoma patients. The data are grouped according to the presence or absence of high P-ERK levels and/or increased levels of PEA3 and/
or ER81 (defined as mRNA levels more than two standard deviations above the mean for the normal samples for each gene). Median relative
expression levels of MMP-1 are indicated for each combination of P-ERK and PEA3/ER81. mRNA expression is calculated relative to 18S ribosomal
RNA. The box plot represents the inter-quartile range and the median value is indicated by the horizontal line. The y axes are split (indicated by
dashed lines) and the high outliers are labelled by case number.
Keld et al. Molecular Cancer 2010, 9:313
http://www.molecular-cancer.com/content/9/1/313
Page 9 of 14pathway signalling plays a critical positive role in PEA3-
driven processes in cell lines and enhanced levels are
also prevalent in advanced stage adenocarcinomas. Our
data therefore demonstrate a broader role for the ERK-
PEA3-MMP-1 axis in tumourigenesis and identify it as a
potentially important component in adenocarcinoma
development and progression.
Our results point to a role for PEA3 subfamily mem-
bers in driving invasion, one of the key transformations
that occur during tumour metastasis. In oesophageal
adenocarcinoma-derived OE33 cells, depletion of PEA3
leads to a reduction in the expression of MMP-1,a n
important player in metastasis (Figure 2) and reduced
invasion (Figure 4). While PEA3 appears to play an
important role in controlling these processes, we cannot
rule out a contributory role for the PEA3 subfamily
member ER81, as depletion of PEA3 leads to reductions
in ER81 levels (Figure 2). Moreover, it is firmly estab-
lished that the ERK pathway leads to PEA3 family acti-
vation [30,31], and in keeping with this observation,
inhibition of ERK signalling blocks invasion and reduces
MMP-1 expression in OE33 cells (Figure 5). Impor-
tantly, these cells exhibit high levels of basal ERK path-
way signalling in the absence of mitogenic stimulation
(Figure 5A). In contrast, Flo1 cells contain little MMP-1
mRNA or protein and very low levels of phospho-ERK
(Figure 5A) despite high levels of ER81 and PEA3 (Fig-
ure 2A) which suggests that the lack of ERK pathway
signalling might be the reason for the lack of MMP-1
expression in these cells. Indeed, activation of the ERK
pathway in Flo1 cells promotes MMP-1 expression.
Thus OE33 cells appear to have been rewired to cause
constitutive high levels of ERK signalling, to express
high levels of PEA3 and ER81 and hence to have high
levels of MMP-1 which can help drive cell invasion.
The relationship between PEA3 and ER81 and target
gene expression is not entirely clear. These two proteins
share considerable sequence homology and have a con-
served domain structure, including an almost identical
DNA binding domain. Thus target gene selection and
activation are likely to proceed in a similar manner.
Interestingly, depletion of ER81 also causes reductions
in MMP-1 levels. However, depletion of ER81 also
causes reductions in PEA3 mRNA levels hinting at
potential cross-regulation. This is even more pro-
nounced in the reciprocal direction where depletion of
PEA3 leads to substantial decreases in ER81 levels. This
is unlikely to be a non-specific effect or chance cross-
hybridisation as four different PEA3 siRNAs cause
reductions in ER81 expression (Figure 2F). This suggests
that there might be reciprocal cross-regulation of ER81
and PEA3 on each others’ expression. Indeed, the
upstream ERK pathway that activates ER81 and PEA3
transactivation capacity is also important for the
expression of both ER81 and PEA3. Further studies are
needed to support this model for mutual cross regula-
tion which might reinforce the expression levels of each
transcription factor. However, the current data suggests
an important role for PEA3 and/or ER81 in promoting
MMP-1 expression and subsequent invasion.
A major finding from our work is that PEA3 is also
important for promoting OE33 cell proliferation. Again,
ERK pathway signalling also has a crucial function in
this context. Additional work is required to determine
the molecular basis to PEA3-driven oesophageal cancer
cell proliferation but MMP-1 expression is unlikely to
account for the altered proliferation as PEA3 siRNA
construct B does not significantly reduce MMP-1 levels
( F i g u r e2 G )b u ti td o e sp r o f o undly affects proliferation
(Figure 4E). A previous study in breast cancer cells sug-
gested a role for PEA3 in proliferation control as it was
shown that PEA3 regulates Cyclin D3 expression, a key
regulator of the cell cycle and affects cell cycle progres-
sion [39]. Moreover, in p53-depleted ovarian cancer
cells, PEA3 has been shown to regulate the p21, a
potent inhibitor of the cell cycle [40]. It is likely that the
expression or activity of key cell cycle regulators such as
cyclin-CDK complexes or their inhibitors are either
directly or indirectly controlled by PEA3 subfamily
members in oesophageal adenocarcinoma cells.
To provide evidence for the existence of the same reg-
ulatory pathway in human adenocarcinoma samples, the
levels of PEA3, ER81, MMP-1 and the activation of the
ERK pathway were monitored. There was a clear co-
upregulation of PEA3 and ER81 with MMP-1 and, to a
lesser extent, MMP-7 in adenocarcinoma samples (Fig-
ure 6B), suggesting a causative role for PEA3 subfamily
members in driving MMP-1 expression. Importantly,
high levels of PEA3 protein expression correlated with
N stage disease (Figure 1C), and a combination of high
PEA3 levels and high ERK activation correlated with
late stage metastatic forms of the disease (Figure 6C).
Thus, enhanced PEA3 levels coincide with molecular
markers of metastasis such as MMP-1 a n da r ef o u n di n
the more advanced metastatic stages of the disease.
While these data are correlative, they are consistent
with our work in oesophageal adenocarcinoma-derived
cell lines and indicate that the ERK-PEA3-MMP-1 axis
likely plays an important role in driving the progression
of oesophageal adenocarcinomas in humans. Impor-
tantly we find little evidence to support a role for the
ERK-PEA3-MMP-1 axis in samples from patients with
Barrett’s metaplasia which is thought to be a forerunner
to the formation of oesophageal adenocarcinomas and
hence potentially represents an early stage of the dis-
ease. Low expression levels of PEA3 subfamily members
and relatively low levels of MMPs are observed Barrett’s
metaplasia samples (Additional file 1: Figures S1 and
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Page 10 of 14S2). We were unable to make meaningful comparisons
between patient samples with Barrett’s oesophagous and
early stage 1 adenocarcinomas and hence the potential
transition period, because to the paucity of samples in
the latter class due to the tendency of patients to pre-
sent with the disease once it has become firmly estab-
lished. The activation status of the ERK-PEA3-MMP-1
axis does however represent a potentially attractive
prognostic indicator of advanced oesophageal
adenocarcinomas.
Conclusions
In summary, this study shows that the ERK-PEA3-
MMP-1 axis is upregulated in oesophageal adenocarci-
n o m ac e l l sw h e r ei tp l a y sar o l ei np r o m o t i n gi n v a s i o n ,
and in the case of the ERK-PEA3 subpart, a role in
enhancing proliferation. Components of the ERK-PEA3-
MMP-1 axis are also upregulated or hyperactivated in
adenocarcinoma samples indicating that this axis is a
potentially important driver of the metastatic progres-
sion of oesophageal adenocarcinomas.
Materials and methods
Tissue collection
Ethical approval was granted by Wrightington Wigan and
Leigh Ethics Committee, UK in 2004. Tissue was col-
lected from 70 patients with oesophageal adenocarcino-
mas, 28 with Barrett’s oesophagus and 55 healthy
controls. Adenocarcinomas at the gastro-oesophageal
junction were classified as oesophageal adenocarcinomas.
Age and date at diagnosis, gender, co-morbidity, smoking
status and survival was recorded. Details of the histologi-
cal grade of tumour and stage, using the TNM and AJCC
criteria were collected. Information on treatments includ-
ing surgery, chemotherapy, radiotherapy and palliation
were also recorded. Biopsy samples, approximately 4 mm
in size, were taken at the time of endoscopic examina-
tion. Biopsy and surgical samples were rapidly frozen in
liquid nitrogen and stored at -80°C until needed. Paraffin
blocks were used to construct tissue microarrays for
immunohistochemistry. Frozen biopsy and surgical sam-
ples were used for RNA extraction.
Cell lines, cell culture and western analysis
OE33, and OE21 (oesophageal adenocarcinoma) cell
lines (kindly provided by Caroline Hill, Cancer Research
UK, LRI), Flo1 and Het1A oesophageal cells (kindly pro-
vided by Laura Hardy, Molecular Epidemiology Unit,
Leeds), 293T and SW480 cells were all grown in
DMEM (Invitrogen) medium except SW480 cells which
were grown in RPMI (Invitrogen) medium. All the cell
lines were grown with 10% foetal bovine serum (FBS)
(Invitrogen) and penicillin (100 units/ml) and strepto-
mycin (100 μg/ml) (P+S) (Invitrogen) at 37°C with 5%
carbon dioxide. Cells were grown with 10 nM PMA, 10
mM U0126 (Sigma®) or the carrier solvent DMSO
(Sigma®) when indicated. Cell lysis was carried out as
previously described [36]. For western analysis, 100 μg
of cell lysate was typically used for SDS-PAGE. Follow-
ing transfer to a nitrocellulose membrane proteins were
detected with either ERK2 (New England Biolabs), pERK
(New England Biolabs), MMP-1 (Abcam Ab38929) or
MMP-7 (Santa Cruz Sc-8832) antibodies.
RNA isolation and RT-PCR analysis
RNA was extracted using RNeasy (Qiagen) according to
the manufacturer’s protocol. Tissue specimens were
additionally treated with DNase I (Qiagen) to remove
DNA contamination. RNA integrity was confirmed in
tissue specimens with a 2100 Bioanalyser with a RNA
6000 Nano Assay Lab Chip® kit (Agilent Technologies,
US). Only specimens with a RIN > 5 were analysed
further. Sybr Green RT-PCR (for real time RT-PCR)
and single step RT-PCR (for semi-quantitative standard
RT-PCR) kits (Qiagen) were utilised according to the
manufacturer’s protocol. The primers used were PEA3,
ADS2679 (5’-GGACTTCGCCTACGACTCAG-3’)a n d
ADS2680 (5’-CGCAGAGGTTTCTCATAGCC-3’); ER81,
ADS2681 (5’-TCCCTCCATCGCAGTCCATA-3’ and
ADS2682 (5’-GGAAAGCTTTGGCTGGCCG-3’); MMP-
1, ADS2669 (5’-GGTCTCTGAGGGTCAAGCAG-3’)
and ADS2670 (5’-AGTTCATGAGCTGCAACACG-3’);
MMP-7, ADS2675 (5’-CCAAATCAACCATAGGTC
CA-3’) and ADS2676 (5’-TTGAGATAGTCCTGAGC
CTG-3’) (for single step RT-PCR); ADS2671 (5’-GAG
TGCCAGATGTTGCAGAA-3’) and ADS2672 (5’-AAA
TGCAGGGGGATCTCTTT-3’) (for real-time RT-PCR);
18S, ADS4005 (5’-CGGCTACCACATCCAAGGAA-3’)
and ADS 4006 (5’-GCTGGAATTACCGCGGCT-3’);
Osteopontin, ADS2673 (5’-TTGCAGTGATTTGCTT
TTGC-3’) and ADS2674 (GTCATGGCTTTCGTTGGA
CT-3’); VEGF ADS2678 (5’-AAGTGGTCCCAG GCT
GCA-3’) and ADS2679 (5’-ACTCCAGGCC CTCGT
CA-3’); GAPDH, ADS2184 (5’-ACAGTCAG CCGCA
TCTTCTT-3’) and ADS2185 (5’-TTGATTTTGGAGGG
ATCTCG-3’). Real time PCR reactions were run on a
Rotor Gene RG-3000 (Corbett) and analysed with Rotor-
Gene 6 software. Data are presented relative to 18S RNA
levels in the same samples. For relative comparison of
mRNA levels from tissue specimens, data were further
normalized to the level of each gene in a standard con-
centration of RNA isolated from OE33 (for MMP-1 and
MMP-7), SW480 (for PEA3) and Flo1 (for ER81) cells.
Immunohistochemistry
Tissue microarray blocks were constructed from surgical
resection tumour blocks and biopsies as follows; three
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precision arraying instrument (Beecher Instruments).
These cores were then arrayed into a new “recipient
block”. Sections (4 μm thick) were cut with a microtome
from each TMA and mounted on adhesive slides (Vision
BioSystems™). One H&E stained slide was made to use
as a reference for the cores. Three arrays were con-
structed for each case and stained with PEA3 (Santa
Cruz Sc 113) and pERK antibodies (New England Bio-
labs #437S) at a 1:20 and 1:100 dilution respectively. A
negative control slide was tested without the primary
antibody to detect any background staining or false
positive results. Three cores for each specimen were
constructed and scored by two histopathologists blinded
to the clinical details. A positive score was determined
by the presence of positive staining in 5% of tumour
cells. An intensity score of 1-4 was also determined.
Moderate to high expression (intensity score 3 and 4)
was judged to be present if staining was visible easily at
×20 magnification. The highest score in the triplet of
cores was recorded. We took moderate to high expres-
sion as positive for PEA3 protein expression.
Invasion assays
2×1 0
5 cells were seeded on the upper, serum free,
8 μm Matrigel chamber and allowed to migrate to a
lower chamber containing 10% FBS. After 24-48 hours,
the upper surface was cleaned with a cotton bud. Cells
on the lower surface were fixed with 4% paraformalde-
hyde (Sigma) and stained with 0.5% Crystal violet
(Sigma). Cells were counted in 10 fields at ×10 magnifi-
cation, the highest scoring outlier field was omitted and
then the average numbers per field from the remaining
9 fields was calculated. The data are presented relative
to a control condition for each experiment. Each experi-
ment was repeated at least three times.
Proliferation assays
Cells that did not stain with Trypan Blue 0.4% (Sigma)
were termed viable. 1-2 × 10
5 viable cells were grown
for 96 hours. Adherent cells were detached using 200 μl
Trypsin 0.05% (Invitrogen). Viable and non viable
cells were counted at 24 hour intervals using a
haemocytometer.
siRNA and plasmid transfection
Short interfering (si) RNAs directed against human
PEA3, ER81, MMP-1 (SMARTpools; Dharmacon), PEA3
(individual deconvoluted SMARTpool constructs; Dhar-
macon) and a non-targeting scrambled sequence (Santa
Cruz) were used. Lipofectamine RNAiMAX (Invitrogen)
was used for siRNA transfection according to the manu-
facturer’s protocols. Lipofectamine 2000 (Invitrogen)
was used for DNA transfection or combined siRNA and
DNA transfection according to the manufacturer’sp r o -
tocol. The final concentration of siRNAs was 10 nM
and the media was replaced after 4-24 hours. The cells
were allowed to grow for a further 24 to 96 hours after
transfection.
Luciferase reporter assays
For reporter gene assays, 15 × 10
4 cells were plated in
each well of a 6 well plate and transfected with vectors
encoding MMP-1-luciferase (pColI-luc containing the
MMP-1 promoter -517/+63) (pAS2701; kindly provided
by Olivier Kassel [42]) (500 ng), pCH110 (100 ng) and
either PEA3 (pAS1801 [36]) (500 ng) or empty
pCDNA3 vector (500 ng). 10 nM siRNA was also added
to the cells. After 48 hours the cells were washed, lysed
and luciferase and b-galactosidase activities determined
according to the kit manufacturer’s instructions (Tropix)
using a TD-20/20 luminometer (Turner Designs). The
luciferase activity for each sample relative to b-galactosi-
dase activity was then calculated.
Additional material
Additional file 1: Figure S1. mRNA expression levels of PEA3 and
ER81 in oesophageal tissue. (A and B) mRNA levels of PEA3 (A) and
ER81 (B) relative to 18S RNA in tissue specimens are presented. All
samples were standardised to expression in SW480 (for PEA3) and Flo1
(for ER81) cell lines and are presented on a log2 scale. The average
relative mRNA levels and standard deviations derived from at least two
readings from one sample are shown. The individual tissue specimens
are numbered. The samples are grouped according to the indicated
oesophageal tissue sub-types. The average gene expression in each
category is shown in red. They axis is split for both genes. Figure S2.
mRNA expression levels of MMP-1 and MMP-7 in oesophageal
tissue. (A and B) mRNA levels of MMP-1 (A) and MMP-7 (B) relative to
18S RNA in tissue specimens are presented. All samples are standardised
to expression in OE33 cells and are presented on a log2 scale. The
average relative mRNA levels and standard deviations derived from at
least two readings from one sample are shown. The individual tissue
specimens are numbered. The samples are grouped according to the
indicated oesophageal tissue sub-types. The average gene expression in
each category is shown in red. They axis is split for both genes.
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